miR‑433 accelerates acquired chemoresistance of gallbladder cancer cells by targeting cyclin M

Yu,Jianhua; Zhang,Weiguang; Lu,Baochun; Qian,Hongwei; Tang,Haijun; Zhu,Zhiyang; Yuan,Xinggui; Ren,Peitu

doi:10.3892/ol.2017.7708

miR‑433 accelerates acquired chemoresistance of gallbladder cancer cells by targeting cyclin M

Authors:
- Jianhua Yu
- Weiguang Zhang
- Baochun Lu
- Hongwei Qian
- Haijun Tang
- Zhiyang Zhu
- Xinggui Yuan
- Peitu Ren
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, Zhejiang 312000, P.R. China, Department of Molecular Medicine and Clinical Laboratory, Shaoxing Second Hospital, Shaoxing, Zhejiang 312000, P.R. China
Published online on: December 28, 2017 https://doi.org/10.3892/ol.2017.7708
Pages: 3305-3312

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Resistance to chemotherapy is associated with dismal prognosis in patients with gallbladder cancer. Cyclin‑dependent kinase 10 (CDK10) influences the chemosensitivity of gallbladder cancer cells, and cyclin M is the activating factor and binding partner of CDK10. To determine the effect of CDK10 or cyclin M overexpression on chemosensitivity, gemcitabine‑resistant (GR) subclones were established from CDK10 or cyclin M stable transfectants. Stable overexpression of CDK10 increased the sensitivity to gemcitabine in non‑resistant cells and did not further increase the sensitivity to gemcitabine in the GR subclones. GR subclones exhibited a significantly decreased expression of cyclin M while maintaining the expression levels of CDK10, compared with the non‑resistant cells. MicroRNA (miR)‑433 was identified as a candidate factor involved in the mechanism of the downregulation of M cyclin in GR subclones. Luciferase assays confirmed the interaction between miR‑433 and the 3' untranslated region (3'UTR) of cyclin M. Additionally, ectopic expression of miR‑433 significantly decreased the expression of cyclin M. Finally, increased expression of circulating miR‑433 was associated with poor outcome of chemotherapy. The results of the present study suggest that miR‑433 is a potential biomarker for evaluating chemosensitivity in gallbladder cancer.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Lai CH and Lau WY: Gallbladder cancer - a comprehensive review. Surgeon. 6:101–110. 2008. View Article : Google Scholar : PubMed/NCBI
3	Goetze TO: Gallbladder carcinoma: Prognostic factors and therapeutic options. World J Gastroenterol. 21:12211–12217. 2015. View Article : Google Scholar : PubMed/NCBI
4	Unger S, Böhm D, Kaiser FJ, Kaulfuss S, Borozdin W, Buiting K, Burfeind P, Böhm J, Barrionuevo F, Craig A, et al: Mutations in the cyclin family member FAM58A cause an X-linked dominant disorder characterized by syndactyly, telecanthus and anogenital and renal malformations. Nat Genet. 40:287–289. 2008. View Article : Google Scholar : PubMed/NCBI
5	Guen VJ, Gamble C, Flajolet M, Unger S, Thollet A, Ferandin Y, Superti-Furga A, Cohen PA, Meijer L and Colas P: CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome. Proc Natl Acad Sci USA. 110:pp. 19525–19530. 2013; View Article : Google Scholar : PubMed/NCBI
6	Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, Tutt AN, Crook T, Lord CJ and Ashworth A: Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell. 13:91–104. 2008. View Article : Google Scholar : PubMed/NCBI
7	Leman ES, Magheli A, Yong KM, Netto G, Hinz S and Getzenberg RH: Identification of nuclear structural protein alterations associated with seminomas. J Cell Biochem. 108:1274–1279. 2009. View Article : Google Scholar : PubMed/NCBI
8	Yu JH, Zhong XY, Zhang WG, Wang ZD, Dong Q, Tai S, Li H and Cui YF: CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells. Oncol Rep. 27:1266–1276. 2012. View Article : Google Scholar : PubMed/NCBI
9	Zhong XY, Xu XX, Yu JH, Jiang GX, Yu Y, Tai S, Wang ZD and Cui YF: Clinical and biological significance of Cdk10 in hepatocellular carcinoma. Gene. 498:68–74. 2012. View Article : Google Scholar : PubMed/NCBI
10	Kasten M and Giordano A: Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity. Oncogene. 20:1832–1838. 2001. View Article : Google Scholar : PubMed/NCBI
11	Lee RC and Ambros V: An extensive class of small RNAs in Caenorhabditis elegans. Science. 294:862–864. 2001. View Article : Google Scholar : PubMed/NCBI
12	Yates LA, Norbury CJ and Gilbert RJ: The long and short of microRNA. Cell. 153:516–519. 2013. View Article : Google Scholar : PubMed/NCBI
13	Xu X, Zhu Y, Liang Z, Li S, Xu X, Wang X, Wu J, Hu Z, Meng S, Liu B, et al: c-Met and CREB1 are involved in miR-433-mediated inhibition of the epithelial-mesenchymal transition in bladder cancer by regulating Akt/GSK-3β/Snail signaling. Cell Death Dis. 7:e20882016. View Article : Google Scholar : PubMed/NCBI
14	Wang XC, Ma Y, Meng PS, Han JL, Yu HY and Bi LJ: miR-433 inhibits oral squamous cell carcinoma (OSCC) cell growth and metastasis by targeting HDAC6. Oral Oncol. 51:674–682. 2015. View Article : Google Scholar : PubMed/NCBI
15	Weiner-Gorzel K, Dempsey E, Milewska M, McGoldrick A, Toh V, Walsh A, Lindsay S, Gubbins L, Cannon A, Sharpe D, et al: Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells. Cancer Med. 4:745–758. 2015. View Article : Google Scholar : PubMed/NCBI
16	Yang Z, Tsuchiya H, Zhang Y, Hartnett ME and Wang L: MicroRNA-433 inhibits liver cancer cell migration by repressing the protein expression and function of cAMP response element-binding protein. J Biol Chem. 288:28893–28899. 2013. View Article : Google Scholar : PubMed/NCBI
17	Guo LH, Li H, Wang F, Yu J and He JS: The tumor suppressor roles of miR-433 and miR-127 in gastric cancer. Int J Mol Sci. 14:14171–14184. 2013. View Article : Google Scholar : PubMed/NCBI
18	Furlong F, Fitzpatrick P, O'Toole S, Phelan S, McGrogan B, Maguire A, O'Grady A, Gallagher M, Prencipe M, McGoldrick A, et al: Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer. J Pathol. 226:746–755. 2012. View Article : Google Scholar : PubMed/NCBI
19	Kroh EM, Parkin RK, Mitchell PS and Tewari M: Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 50:298–301. 2010. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 50:402–408. 2001. View Article : Google Scholar
21	Tekcham DS and Tiwari PK: Non-coding RNAs as emerging molecular targets of gallbladder cancer. Gene. 588:79–85. 2016. View Article : Google Scholar : PubMed/NCBI
22	Oliveto S, Mancino M, Manfrini N and Biffo S: Role of microRNAs in translation regulation and cancer. World J Biol Chem. 8:45–56. 2017. View Article : Google Scholar : PubMed/NCBI
23	Yu J, Zhang W, Tang H, Qian H, Yang J, Zhu Z, Ren P and Lu B: Septin 2 accelerates the progression of biliary tract cancer and is negatively regulated by mir-140-5p. Gene. 589:20–26. 2016. View Article : Google Scholar : PubMed/NCBI
24	Williams TM, Majithia L, Wang SJ and Thomas CR Jr: Defining the role of adjuvant therapy: Cholangiocarcinoma and gall bladder cancer. Semin Radiat Oncol. 24:94–104. 2014. View Article : Google Scholar : PubMed/NCBI
25	Phelip JM, Vendrely V, Rostain F, Subtil F, Jouve JL, Gasmi M, Michel P, Le Malicot K, Smith D, Seitz JF, et al: Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. Eur J Cancer. 50:2975–2982. 2014. View Article : Google Scholar : PubMed/NCBI
26	Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 362:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
27	Li X, Yang L, Shuai T, Piao T and Wang R: miR-433 inhibits retinoblastoma malignancy by suppressing Notch1 and PAX6 expression. Biomed Pharmacother. 82:247–255. 2016. View Article : Google Scholar : PubMed/NCBI
28	Liang T, Guo Q, Li L, Cheng Y, Ren C and Zhang G: MicroRNA-433 inhibits migration and invasion of ovarian cancer cells via targeting Notch1. Neoplasma. 63:696–704. 2016. View Article : Google Scholar : PubMed/NCBI